Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.
Actively Recruiting
Researchers are studying tirzepatide to understand its effects on weight loss and the development of type 2 diabetes in adults who have obesity but do not have diabetes. This phase 4 study takes place in a real-world setting and aims to compare tirzepatide to standard care for these adults who also have at least one health condition related to their weight. The study is sponsored by Eli Lilly and Company and includes participants who are registered patients at participating sites. Participants will be randomly assigned to receive either tirzepatide injections once weekly along with standard care or standard care alone. The study will last about 260 weeks approximately 5 years, allowing researchers to observe long-term effects. The main focus is on how much participants body weight changes from the start of the study after 24 months, as well as whether they develop type 2 diabetes or other health complications related to obesity over 60 months. Throughout the study, participants will have various health measurements taken, including weight, waist size, blood pressure, cholesterol levels, liver enzymes, and quality of life assessments. Researchers will track the time it takes for participants to develop type 2 diabetes and monitor changes in blood sugar control and other health markers. Participants health resource use and overall wellbeing will also be evaluated. These assessments help understand the impact of tirzepatide compared to standard care over the long term.
Actively Recruiting
Researchers are studying the safety of two propellant components used in metered dose inhalers MDIs for people with asthma. The study compares a newer propellant called HFA-152a with the commonly used HFA-134a to gather more safety information. This is a Phase 3 randomized study designed to evaluate these propellants when delivered via inhalers. Participants will receive both propellants in two separate treatment periods in a crossover design. Some will use HFA-152a first followed by HFA-134a, while others will receive them in the reverse order. A washout period occurs between the two treatment phases to clear the first propellant before starting the second. During the study, participants will be closely monitored for any adverse events up to 8 weeks. Vital signs such as blood pressure, pulse rate, heart rate, and ECG readings will be measured at specific times. Researchers will assess safety by looking at changes from baseline and any serious side effects. The total participation length covers both treatment periods and follow-up assessments.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.
Actively Recruiting
Diabetes mellitus is a widespread condition that requires regular monitoring of blood sugar levels to prevent complications. This research aims to evaluate the accuracy, patient acceptance, and economic impact of home-based self-collection of blood samples compared to the standard venous blood draws performed by healthcare professionals. The study focuses on key blood tests including HbA1c, lipids, and thyroid function, addressing challenges like long clinic wait times and limited healthcare access, especially in rural areas. Participants will first visit the clinic for a routine venous blood draw. They will then be randomly assigned to perform a self-collection of capillary blood either via finger prick or an upper arm device while in the clinic, with training provided. Following this, participants will take a similar blood sample at home within two days and send it via prepaid mail to the laboratory. Questionnaires will be completed after both in-clinic and home collections to assess their experience and preferences. Throughout the study, researchers will monitor sample quality, temperature during transit, and participant compliance. Results from all samples will be compared to assess accuracy. Patient feedback on ease and convenience of self-collection will be analyzed alongside cost considerations. The study will last up to 12 months, with final results informing the potential for home blood collection to improve diabetes monitoring and reduce healthcare burdens.
Actively Recruiting
Researchers are evaluating whether cognitive analytic therapy-guided self-help CAT-GSH is as effective and acceptable as cognitive behavioural therapy-guided self-help CBT-GSH for people with anxiety or depression returning to NHS Talking Therapies services for further treatment. The study aims to compare outcomes between those returning and those using CBT-GSH for the first time, considering factors like age. This is a prospective, quasi-experimental study involving participants who have previously received CBT-GSH. Participants choose between CAT-GSH and CBT-GSH treatments, each consisting of six one-to-one guided self-help sessions lasting 35 minutes. Sessions occur weekly or bi-weekly and can be face-to-face, online, or by telephone. Psychological wellbeing practitioners PWPs deliver the therapies and record the third session for competency review by the research team. The study collects routine outcome measures during and after treatment. Participants are identified during initial assessments and complete consent procedures by phone or email. Before, during, and after therapy, routine measures such as the Generalised Anxiety Disorder-7 GAD-7, Patient Health Questionnaire-9 PHQ-9, and Work and Social Adjustment Scale WSAS are collected to assess treatment outcomes over 6 to 12 weeks. The research team will analyze these data starting December 2025 to compare the effectiveness and acceptability of CAT-GSH versus CBT-GSH for returning patients.
Actively Recruiting
Researchers are studying the performance and safety of a nitric oxide generating dressing called ConvaNiox in treating diabetic foot ulcers DFUs. This observational study aims to gather real-world evidence on how well this device works and its safety profile for patients with diabetes-related foot ulcers. It is sponsored by ConvaTec Inc. and focuses on adults with type 1 or type 2 diabetes who have specific types of foot ulcers. Participants will receive their standard care for diabetic foot ulcers but will use the ConvaNiox device as their primary dressing instead of their usual one. The study does not involve assigning treatments randomly but observes the outcomes of using this dressing as part of routine care. The device is applied during regular visits, and the study will monitor participants over a period of at least 12 weeks. During the study, participants will undergo assessments including measuring the percentage of ulcer area reduction at 4 and 12 weeks and tracking the incidence of wound closure. Researchers will also evaluate ulcer infections and arterial supply adequacy. Follow-up visits will involve clinical evaluations and data collection to assess the dressings effects, with the main outcome being the percentage of ulcer area reduction after 12 weeks of treatment.
Actively Recruiting
Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.
1-10 of 12
1